Lipids and Atherosclerosis Annual 2003

✍ Scribed by Allan Gaw, James Shepherd

• Year: 2003
• Tongue: English
• Leaves: 163
• Edition: 1
• Category: Library

✦ Synopsis

Given the continuing development of new statins and their increasing beneficial use in clinical practice as well as the importance of clinical research into the atherosclerotic plaque and its role in cardiovascular and endovascular diseases, Gaw and Shepherd have chosen topics on lipids and atherosclerosis that are of current interest for researchers and clinicians alike. This edition of the Lipids and Atherosclerosis Annual includes chapters on topics of current interest, including the long-term safety of lipid-lowering drugs, the implications of statin therapy on CHD prevention, and drug combination strategies for vascular disease prevention.

✦ Table of Contents

Book Cover......Page 1
Half-Title......Page 2
Title......Page 3
Copyright......Page 4
Contents......Page 6
Contributors......Page 7
Preface......Page 11
Introduction......Page 12
Role of inflammation in atherogenesis......Page 13
Inflammatory markers and coronary heart disease......Page 14
Statins and immunosuppression......Page 15
Statins, CRP and risk for CHD......Page 17
Statins, endothelial function and plaque stability......Page 18
Type 2 diabetes......Page 19
Rheumatoid arthritis......Page 20
References......Page 21
Rheological principles......Page 25
Determinants of blood rheology......Page 26
Importance of rheology in atherosclerosis......Page 28
Viscosity and ischemic heart disease......Page 29
Effects of lipoproteins on rheology......Page 31
Lipid-lowering therapy and rheology......Page 32
Clinical significance of lipoprotein-mediated hyperviscosity......Page 33
References......Page 34
Introduction......Page 38
PPAR agonists......Page 39
Clinical actions of PPARα agonists......Page 40
Effects of PPARα agonists on triglyceride metabolism......Page 41
Effects of PPARα agonists on the reverse cholesterol transport pathway......Page 43
PPARγ agonists in the control of diabetic dyslipidaemia......Page 45
PPARδ(β) agonists: new molecules in the control of lipid homeostasis?......Page 46
References......Page 47
Scope of the clinical problem......Page 54
Scientific rationale for lipid-lowering after ACS......Page 55
Observational studies......Page 56
Randomized controlled trials......Page 58
Unanswered questions......Page 60
References......Page 61
Magnitude of effect......Page 64
Effects of different statins on HDL cholesterol......Page 65
HDL-raising effects of statins compared with other drugs......Page 66
Increased synthesis of apoA-I......Page 67
Mechanism underlying possible differences in the HDL-raising properties of statins......Page 68
Statin trials......Page 69
Relationship between HDL cholesterol and coronary events in fibrate trials......Page 72
Conclusion......Page 74
References......Page 75
Statins......Page 78
Skeletal muscle toxicity......Page 79
Fibrates......Page 81
Nicotinic acid......Page 82
Ezetimibe......Page 83
References......Page 84
Background......Page 87
Preventive strategies......Page 88
Diagnostic misclassification......Page 89
The use of DNA-based mutation testing......Page 90
Criteria for screening......Page 91
Treatment......Page 92
Screening programmes......Page 94
References......Page 96
Introduction......Page 100
Mechanism of action of phytosterols......Page 101
Comparative studies of plant sterol and stanol esters......Page 102
ω3 fatty acids......Page 105
Studies of ω3 fatty acid intake and risk of CHD......Page 106
Mechanism of the cardioprotective action of ω3 fatty acids......Page 107
Garlic......Page 108
Soya protein and phytoestrogens......Page 109
Guar gum......Page 110
Conclusion......Page 111
References......Page 112
Meaning of compliance......Page 115
Assessing compliance levels......Page 116
Design and purpose of original studies......Page 117
Physical......Page 118
Drug scheduling/compliance history......Page 121
Psychological factors......Page 122
Summary of trial results......Page 124
Health beliefs......Page 125
Limitations of theoretical models......Page 127
References......Page 128
Risk factors......Page 131
The early statin trials......Page 132
Europe, UK and USA......Page 133
Lipid targets......Page 134
Hyperlipidaemia in the elderly......Page 135
Patients at risk of stroke......Page 138
Metabolic syndrome......Page 139
The SCORE project......Page 140
Treatment gap......Page 141
Start statins in hospital......Page 143
Acknowledgements......Page 144
References......Page 145
Appendix to Chapter 10......Page 148
Index......Page 153